GNRH1 and prostate carcinoma: Among 22,310 men with prostate cancer followed for an average of 3.9 years, ADT use was associated with the development of stroke/TIA, specifically GnRH agonists (adjusted RR 1.18, 95% CI 1.00–1.39), oral anti-androgens (adjusted RR 1.47, 95% CI 1.08–2.01), and those who underwent bilateral orchiectomy (adjusted RR 1.77, 95% CI 1.25– 2.39) [48].